Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders.

Abstract

Prostate carcinoma is the most frequently diagnosed malignancy and the second leading cause of death as a result of cancer in men in the US and other parts of the world. There are conflicting reports on the serum levels of testosterone and 17β-estradiol (E2) in benign prostatic hyperplasia (BPH) and prostate cancer. This study was designed to evaluate the serum concentrations of these hormones in patients with these disorders. Serum levels of prostate specific antigen (PSA), total testosterone and estradiol were determined in 228 subjects comprising of 116 subjects with BPH, 62 subjects with prostate cancer (CaP) and 50 age-matched apparently healthy controls, using ELISA methods. PSA levels were significantly elevated (p<0.05) in BPH subjects than controls, while there was no significant difference (p>0.05) in testosterone and estradiol levels of these subjects. PSA and estradiol levels were significantly higher (p<0.05) in CaP subjects than in controls, while there was no observed significant difference (p>0.05) in testosterone levels. CaP subjects had significantly raised PSA, testosterone, and estradiol levels than BPH subjects. The mean molar ratio of testosterone: E2 was lowest among CaP patients (134:1) and highest among controls (166:1). Significant positive correlation between PSA and 17β-estradiol was observed in prostate disorders (BPH and CaP patients: r=0.347; p=0.000). Significant negative correlations between testosterone and PSA were also observed among BPH patients (r=-0.221, p=0.049) and control subjects (r=-0.490, p=0.000). No significant correlation existed between testosterone and PSA in CaP patients (r=0.051, p=0.693). Correlations between age and estradiol in both BPH and CaP were not significant (p>0.05). This study has shown that, there was a significant increase in serum estradiol in CaP subjects, while the testosterone levels in both BPH and CaP subjects were not different from those of controls.